Chronic antidepressant treatment accelerates kindling epileptogenesis in rats

Neurobiology of Disease

Volumn 63, Issue , 2014, Pages 194-200

  Cardamone, Lisa ^a   Salzberg, Michael R ^a,b   Koe, Amelia S ^a   Ozturk, Ezgi ^a   O'Brien, Terence J ^a   Jones, Nigel C ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b St Vincent's Mental Health Service   (Australia)

Author keywords

Animal model; Antidepressant; Depression; Epilepsy; Epileptogenesis; Kindling; Selective serotonin reuptake inhibitor

Indexed keywords

CITALOPRAM; FLUOXETINE; MESSENGER RNA; NORFLUOXETINE; PLACEBO; SEROTONIN 1A RECEPTOR; SEROTONIN TRANSPORTER;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHRONIC DRUG ADMINISTRATION; CONTINUOUS INFUSION; CONTROLLED STUDY; DEPRESSION; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG EFFECT; ELECTROSTIMULATION; EPILEPTOGENESIS; GENE EXPRESSION; KINDLING; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SEIZURE; SEIZURE THRESHOLD;

ANIMAL MODEL; ANTIDEPRESSANT; DEPRESSION; EPILEPSY; EPILEPTOGENESIS; KINDLING; SELECTIVE SEROTONIN REUPTAKE INHIBITOR;

AMYGDALA; ANALYSIS OF VARIANCE; ANIMALS; ANTIDEPRESSIVE AGENTS; BONDING, HUMAN-PET; DRUG DELIVERY SYSTEMS; ELECTRIC STIMULATION; EPILEPSY; FLUOXETINE; GENE EXPRESSION REGULATION; KINDLING, NEUROLOGIC; MALE; RATS; RATS, WISTAR; RECEPTOR, SEROTONIN, 5-HT1A; RNA, MESSENGER; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS;

EID: 84891302697     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2013.11.020     Document Type: Article

References (49)

1. Alper K., et al. Seizure incidence in psychopharmacological clinical trials: an analysis of Food and Drug Administration (FDA) summary basis of approval reports. Biol. Psychiatry 2007, 62:345-354.
2. Bagdy G., et al. Serotonin and epilepsy. J. Neurochem. 2007, 100:857-873.
3. Borowicz K.K., et al. Chronically administered fluoxetine enhances the anticonvulsant activity of conventional antiepileptic drugs in the mouse maximal electroshock model. Eur. J. Pharmacol. 2007, 567:77-82.
4. Boylan L.S., et al. Depression but not seizure frequency predicts quality of life in treatment-resistant epilepsy. Neurol. 2004, 62:258-261.
5. Cardamone L., et al. Antidepressant therapy in epilepsy: can treating the comorbidities affect the underlying disorder?. Br. J. Pharmacol. 2013, 168:1531-1554.
6. Czachura J.F., Rasmussen K. Effects of acute and chronic administration of fluoxetine on the activity of serotonergic neurons in the dorsal raphe nucleus of the rat. Naunyn Schmiedebergs Arch. Pharmacol. 2000, 362:266-275.
7. Ferrero A.J., et al. Chronic treatment with fluoxetine decreases seizure threshold in naive but not in rats exposed to the learned helplessness paradigm: correlation with the hippocampal glutamate release. Prog. Neuropsychopharmacol. Biol. Psychiatry 2005, 29:678-686.
8. Gaitatzis A., et al. The epidemiology of the comorbidity of epilepsy in the general population. Epilepsia 2004, 45:1613-1622.
9. Gariboldi M., et al. Stimulation of 5-HT1A receptors in the dorsal hippocampus and inhibition of limbic seizures induced by kainic acid in rats. Br. J. Pharmacol. 1996, 119:813-818.
10. Goldberg E.M., Coulter D.A. Mechanisms of epileptogenesis: a convergence on neural circuit dysfunction. Nat. Rev. Neurosci. 2013, 14:337-349.
11. Goodnick P., Goldstein B. Selective serotonin reuptake inhibitors in affective disorders.II. Efficacy and quality of life. Psychopharmacol. 1998, 3:S21-S54.
12. Hasler G., et al. 5-HT1A receptor binding in temporal lobe epilepsy patients with and without major depression. Biol. Psychiatry 2007, 62:1258-1264.
13. Hernandez E.J., et al. Effects of fluoxetine and TFMPP on spontaneous seizures in rats with pilocarpine-induced epilepsy. Epilepsia 2002, 43:1337-1345.
14. Hesdorffer D.C., et al. Major depression is a risk factor for seizures in older adults. Ann. Neurol. 2000, 47:246-249.
15. Hesdorffer D.C., et al. Depression and suicide attempt as risk factors for incident unprovoked seizures. Ann. Neurol. 2006, 59:35-41.
16. Hesdorffer D.C., et al. Epilepsy, suicidality, and psychiatric disorders: a bidirectional association. Ann. Neurol. 2012, 72:184-191.
17. Hesketh S., et al. Differential actions of acute and chronic citalopram on the rodent hypothalamic-pituitary-adrenal axis response to acute restraint stress. J. Endocrinol. 2005, 185:373-382.
18. Igelstrom K.M. Preclinical antiepileptic actions of selective serotonin reuptake inhibitors-implications for clinical trial design. Epilepsia 2012, 53:596-605.
19. Jones N.C., et al. Anxiolytic effects of rapid amygdala kindling, and the influence of early life experience in rats. Behav. Brain Res. 2009, 203:81-87.
20. Jones N.C., et al. Repeatedly stressed rats have enhanced vulnerability to amygdala kindling epileptogenesis. Psychoneuroendocrinology 2013, 38:263-270.
21. Kabuto H., et al. Chronic administration of citalopram inhibited El mouse convulsions and decreased monoamine oxidase-A activity. Acta Med. Okayama 1994, 48:311-316.
22. Kabuto H., et al. The anticonvulsant effect of citalopram on El mice, and the levels of tryptophan and tyrosine and their metabolites in the brain. Neurochem. Res. 1994, 19:463-467.
23. Kalynchuk L.E., et al. Serotonin receptor binding and mRNA expression in the hippocampus of fearful amygdala-kindled rats. Neurosci. Lett. 2006, 396:38-43.
24. Kanner A.M. Depression and epilepsy: a new perspective on two closely related disorders. Epilepsy Curr. 2006, 6:141-146.
25. Kanner A.M. Epilepsy, suicidal behaviour, and depression: do they share common pathogenic mechanisms?. Lancet Neurol. 2006, 5:107-108.
26. Kanner A.M. Depression and epilepsy: a review of multiple facets of their close relation. Neurol. Clin. 2009, 27:865-880.
27. Kanner A.M. Can neurobiological pathogenic mechanisms of depression facilitate the development of seizure disorders?. Lancet Neurol. 2012, 11:1093-1102.
28. Karpova N.N., et al. Fear erasure in mice requires synergy between antidepressant drugs and extinction training. Science 2011, 334:1731-1734.
29. Le Poul E., et al. Differential adaptation of brain 5-HT1A and 5-HT1B receptors and 5-HT transporter in rats treated chronically with fluoxetine. Neuropharmacology 2000, 39:110-122.
30. Mazarati A., et al. Depression after status epilepticus: behavioural and biochemical deficits and effects of fluoxetine. Brain 2008, 131:2071-2083.
31. Morimoto K., et al. Kindling and status epilepticus models of epilepsy: rewiring the brain. Prog. Neurobiol. 2004, 73:1-60.
32. Nestler E.J., et al. Neurobiology of depression. Neuron 2002, 34:13-25.
33. Ni Y.G., Miledi R. Blockage of 5HT2C serotonin receptors by fluoxetine (Prozac). Proc. Natl. Acad. Sci. U. S. A. 1997, 94:2036-2040.
34. Parsons L.H., et al. 5-HT1A receptor mutant mice exhibit enhanced tonic, stress-induced and fluoxetine-induced serotonergic neurotransmission. J. Neurochem. 2001, 77:607-617.
35. Paxinos G., Watson C. The Rat Brain in Stereotaxic Coordinates 1998, Academic Press, San Diego.
36. Peng L., Huang J. Astrocytic 5-HT(2B) receptor as in vitro and in vivo target of SSRIs. Recent Pat. CNS Drug. Discov. 2012, 7:243-253.
37. Racine R.J. Modification of seizure activity by electrical stimulation. I. After-discharge threshold. Electroencephalogr. Clin. Neurophysiol. 1972, 32:269-279.
38. Racine R.J. Modification of seizure activity by electrical stimulation. II. Motor seizure. Electroencephalogr. Clin. Neurophysiol. 1972, 32:281-294.
39. Raju S.S., et al. Effect of fluoxetine on maximal electroshock seizures in mice: acute vs chronic administration. Pharmacol. Res. 1999, 39:451-454.
40. Salzberg M.R., Vajda F.J. Epilepsy, depression and antidepressant drugs. J. Clin. Neurosci. 2001, 8:209-215.
41. Santarelli L., et al. Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science 2003, 301:805-809.
42. Sarnyai Z., et al. Impaired hippocampal-dependent learning and functional abnormalities in the hippocampus in mice lacking serotonin(1A) receptors. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:14731-14736.
43. Stahl S.M. Mechanism of action of serotonin selective reuptake inhibitors. Serotonin receptors and pathways mediate therapeutic effects and side effects. J. Affect. Disord. 1998, 51:215-235.
44. Theodore W.H., et al. Reduced hippocampal 5HT1A PET receptor binding and depression in temporal lobe epilepsy. Epilepsia 2007, 48:1526-1530.
45. Vermoesen K., et al. The antidepressants citalopram and reboxetine reduce seizure frequency in rats with chronic epilepsy. Epilepsia 2012, 53:870-878.
46. Vezzani A., et al. The role of inflammation in epilepsy. Nat. Rev. Neurol. 2011, 7:31-40.
47. Wada Y., et al. Effects of the 5-HT3 receptor agonist 1-(m-chlorophenyl)-biguanide in the rat kindling model of epilepsy. Brain Res. 1997, 759:313-316.
48. Wada Y., et al. Role of serotonin receptor subtypes in the development of amygdaloid kindling in rats. Brain Res. 1997, 747:338-342.
49. Watanabe K., et al. The effect of the acute administration of various selective 5-HT receptor antagonists on focal hippocampal seizures in freely-moving rats. Eur. J. Pharmacol. 2000, 398:239-246.